A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19+
SponsorAddpharma Inc.

About this trial

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.

Eligibility criteria

Qualifiers

Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit

The Age equal to or greater than 19 in healthy volunteers at the time of screening visit

Disqualifiers

Participation in other clinical study with an investigational drug within the 6 months from scheduled first administration

Other exclusions applied

Trial design

Treatments tested in this trial

  • AD-228B
  • AD-2284

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators